Expression of Enzymatically Inactive Wasp Venom Phospholipase A1 in Pichia pastoris

Borodina, Irina; Jensen, Bettina M.; Wagner, Tim; Abou Hachem, Maher; Søndergaard, Ib; Poulsen, Lars Kærgaard

Published in:
P L o S One

Link to article, DOI:
10.1371/journal.pone.0021267

Publication date:
2011

Document Version
Publisher's PDF, also known as Version of record

Link back to DTU Orbit

Citation (APA):

General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
Expression of Enzymatically Inactive Wasp Venom Phospholipase A1 in Pichia pastoris

Irina Borodina¹, Bettina M. Jensen², Tim Wagner¹, Maher A. Hachem³, Ib Søndergaard¹, Lars K. Poulsen²*

¹ Center for Microbial Biotechnology, Institute of Systems Biology, Technical University of Denmark, Kgs. Lyngby, Denmark
² Allergy Clinic, Dermato-Allergological Dept. K, CUH-Gentofte, Righospitalet Dept 7551, København Ø, Denmark
³ Enzyme and Protein Center, Institute of Systems Biology, Technical University of Denmark, Kgs. Lyngby, Denmark

Abstract

Wasp venom allergy is the most common insect venom allergy in Europe. It is manifested by large local reaction or anaphylactic shock occurring after a wasp sting. The allergy can be treated by specific immunotherapy with whole venom extracts. Wasp venom is difficult and costly to obtain and is a subject to composition variation, therefore it can be advantageous to substitute it with a cocktail of recombinant allergens. One of the major venom allergens is phospholipase A1, which so far has been expressed in Escherichia coli and in insect cells. Our aim was to produce the protein in secreted form in yeast Pichia pastoris, which can give high yields of correctly folded protein on defined minimal medium and secretes relatively few native proteins simplifying purification. Residual amounts of enzymatically active phospholipase A1 could be expressed, but the venom protein had a deleterious effect on growth of the yeast cells. To overcome the problem we introduced three different point mutations at the critical points of the active site, where serine137, aspartate165 or histidine229 were replaced by alanine (S137A, D165A and H229A). All the three mutated forms could be expressed in P. pastoris. The H229A mutant did not have any detectable phospholipase A1 activity and was secreted at the level of several mg/L in shake flask culture. The protein was purified by nickel-affinity chromatography and its identity was confirmed by MALDI-TOF mass spectrometry. The protein could bind IgE antibodies from wasp venom allergic patients and could inhibit the binding of wasp venom to IgE antibodies specific for phospholipase A1 as shown by Enzyme Allergo-Sorbent Test (EAST). Moreover, the recombinant protein was allergic in a biological assay as demonstrated by its capability to induce histamine release of wasp venom-sensitive basophils. The recombinant phospholipase A1 presents a good candidate for wasp venom immunotherapy.

Introduction

Allergy to wasp Vespula vulgaris and Vespula germanica venom is the most common insect sting allergy in temperate Europe and is a cause of significant morbidity, impairment of life quality and can sometimes be fatal [1]. Epidemiologic studies report prevalence of systemic anaphylactic reactions in general population at 1–1.5% [2,3]. Patients can be treated by specific immunotherapy (SIT) with venom extract, which is obtained in a tedious and expensive procedure where venom sacs are manually removed from collected wasps and then the extract is partially purified. The extract is subject to composition variation, which can cause adverse effects during treatment; furthermore it contains a number of non-allergenic proteins [4]. Using recombinant allergens as a vaccine instead of the venom extract could improve the treatment of wasp venom allergies by providing a cheaper, well-characterized, and composition-consistent vaccine. Additionally the vaccine components could be combined differently to match individual patients’ sensitization profiles.

One V. vulgaris sting injects around 1.7–3.1 μg of venom, in which the most abundant allergenic proteins (major allergens) are phospholipase A1 (Ves v 1.0101), hyaluronidase (Ves v 2.0101) and antigen 5 (Ves v 5.0101), accounting for correspondingly 3.3%, 1.5% and 8.1% of the total venom protein [5]. A close homologue to hyaluronidase, though without enzymatic activity, allergen Ves v 2.0201 has been found [6,7]. Recently IgE reactivity and basophils activation has also been shown for a high-molecular mass venom component, 100 kDa dipeptidyl peptidase IV (Ves v 3.0101) [8]. Allergens from V. vulgaris have been recombinantly expressed in various hosts as E. coli, insect cells and yeast species.

Antigen 5, a 23 kDa non-glycosylated protein with so far unknown function, has been expressed in E. coli [9,10], P. pastoris [9], insect cells [11] and recently also on the surface of yeast Saccharomyces cerevisiae [12]. Antigen 5 produced in P. pastoris has recently become commercially available for diagnostic purposes in ImmunoCAP format (Phadia, Sweden).

Hyaluronidase, 45-kDa glycosylated protein, catalyzing hyaluronic acid degradation and thus facilitating spreading of venom components in the tissue after sting, has been expressed in E. coli [13,14] and in insect cells [15]. The protein expressed in E. coli did not obtain enzymatic activity after refolding procedure [14] and
had a lower reactivity towards antibodies specific for the native hyaluronidase, indicating that parts of the discontinuous epitopes were lost due to improper folding [13]. It has been hypothesized that glycosylation is important for enzymatic activity and possibly also for correct folding of hyaluronidase [16]. The importance of hyaluronidase for allergic response to wasp venom is probably low as Ves v 2 -specific antibodies are mainly directed towards cross-reactive carbohydrate determinates [15,17], which are believed to be of low (if any) clinical significance [18].

Phospholipase A1, a 33.4 kDa non-glycosylated protein, removes the 1st acyl group from phospholipids and thus causes damage to cell membranes. Phospholipase A1, expressed in E. coli had a lower binding to antibodies specific for the native phospholipase A1 than the native phospholipase A1, suggesting that the recombinant phospholipase A1 was not correctly folded [13]. Enzymatically active and an inactivated variant with two mutations in the putative active site (S137G and D165A) have been expressed in insect cells, both variants were biologically active [11].

While insect cells can provide allergens useful for diagnostic tests [11,19], the system is less suited for making proteins for therapeutic applications because of low yields, difficulties with scale-up, complex purification process and legal issues. In spite of the long history of baculovirus expression system, only one baculovirus-derived product has been approved by Federal Drug Administration (FDA) so far, namely Cervarix, manufactured by GlaxoSmithKline (UK) [20]. An alternative expression system for inexpensive protein secretion is yeast, where particularly P. pastoris has been extensively used recently with several products in the clinical trials pipeline [21,22] and one FDA-approved product – Kalbitor (Dyax, USA) [20].

The aim of this study was to express enzymatically inactivated variants of phospholipase A1 from V. vulgaris in methylotrophic yeast P. pastoris, which is well-suited for industrial-scale fermentations due to strain stability, high level of foreign protein secretion, ability to grow to high cell densities on defined minimal medium and low level of secretion of native proteins.

Materials and Methods

Ethics statement

The Ethical Committee for the Capital Region of Denmark approved the use of historical blood samples in the project, since the patients had already given their informed consent to the storage and scientific use of their serum samples when their blood was originally drawn. The informed consent procedure was written and verbal. At their first visit to the clinic, the patient is informed that if he or she consents the sample will be stored for possible future analyses relating to his/her treatment and for possible research and development. In case of acceptance by the patient, an informed consent form is signed by the patient, in which it is stated that the patient accept that his/her sample is transferred to a 500-ml baffled shake flask and induction was transferred to a 500-ml baffled shake flask and induction was

Patients

Twenty two patients were chosen based on their serum IgE reactivity with venom extract (i3) in ImmunoCap assay (Phadia), all CAP class 4 or above, and non-detected cross-reactivity with honey bee venom (1, <0.33 kUa/L). The negative control sera consisted of a pool of 200 non-allergic sera (negative for common inhalation allergens (birch, grass, mugwort, horse, dog, cat, house dust mites and molds) and food allergens (milk, egg white, cod, peanut, soy bean, wheat flour).

Chemicals

The chemicals were purchased from Sigma-Aldrich and BD Biosciences. Zeocin™ was purchased from Invitrogen. The Anti-His horse radish peroxidase conjugated antibody was a mouse monoclonal IgG1 antibody (Qiagen). The restriction enzymes and T4 DNA ligase were purchased from New England Biolabs Inc. Vespula venom extract (1,000 SQU/µl) used in ELISA was a kind gift from Jorgen Nedergaard Larsen (ALK Abelló, Horsholm, Denmark). Vespula venom extract used in histamine release assay was from ALK Abelló and contained 136 µg/ml protein. The primers were ordered from Eurofins MWG Operon (Germany).

Strains and plasmids

The E. coli strain used for cloning was DH5α (F− Φ80lacZAM15 Δ(lacZYA-argF)U169 deoR recA1 endA1 hsdR17(ri– m–) phoA supE44 thi-1 gyrA96 relA1 r−). The P. pastoris strains used for protein expression were X33 (Mut+ and KM71H (Mut−, arg4 aux1::ARG4) (Invitrogen). Vector pPICZαA was also purchased from Invitrogen. For longer storage the E. coli strains were stored in LB medium with 25% glycerol and yeast strains were stored in YPD (1% yeast extract, 2% peptone, 2% dextrose) with 15% glycerol at −80°C.

Cloning and mutation of phospholipase A1 gene

The Vesv1 gene encoding phospholipase A1 was previously cloned from local Danish V. vulgaris insects [12]. The gene was codon-optimized using online tool from Mr.Gene GmbH (Germany) and synthesized by the same company. The gene was amplified with vesv1_fw and vesv1_rv primers, the fragment was purified from the 1% agarose gel, digested with Xhol and XbaI and ligated into pPICZαA plasmid, digested with the same enzymes and gel-purified. The ligation mixture was transformed into E. coli DH5α cells and the transformants were selected on low salt Luria-Bertani (LB) medium with 25 µg/ml zeocin. The presence of the insert in the plasmid was tested by colony PCR and the correct transformants were grown overnight in liquid low-salt LB medium with zeocin selection after which the plasmids were isolated. The correct cloning of the Vesv1 gene was confirmed by restriction analysis and sequencing (StarSEQ, Germany).

The plasmid was mutared by site-directed mutagenesis using QuickChange® II XL Site-Directed Mutagenesis kit from Stratagene (USA). The primers used in pairs to generate three mutations are given in Table 1.

Yeast transformation

The 4 constructed plasmids were linearized with Sall and transformed into P. pastoris strains X33 and KM71H using the optimized electroporation protocol by Wu and Letchworth [23]. The transformants were selected on YPDS medium (same as YPD, but with additionally 1 M sorbitol) with 100 µg/ml zeocin and streak-purified. The integration of the plasmids in the yeast genome was confirmed by colony PCR.

Cultivation and induction of yeast cells

For X33 Mut− strains a single colony was inoculated into 50 ml BMGY (buffered minimal glycerol medium, recipe from Invitrogen) in 500-ml baffled shake flask and grown for 16 hours at 30°C with shaking at 150 rpm. The OD600 of the culture was measured and a suitable volume was centrifuged to give on resuspension in BMMY (buffered minimal methanol medium) an OD600 of 1. The BMMY medium contained 1% methanol and additionally 1% casamino acids. 25 ml of cells resuspended in BMMY was transferred to a 500-ml baffled shake flask and induction was
carried out either at 20°C or 30°C at 150 rpm rotation for 72 hours with daily addition of 1% methanol.

For MutS strains a single colony was inoculated into 200 ml BMMY medium and grown as for Mut+ strains for 24 hours. The culture was centrifuged and resuspended in 50 ml BMMY medium containing 0.5% methanol, 0.5% glycerol and 1% casamino acids. The cell suspension was divided into 2 shake flasks, 25 ml in each, which were induced at 20°C and 30°C for 72 hours with daily addition of 1% of 1:1 mixture (v/v) of glycerol and methanol.

During the cultivation 1 ml samples were withdrawn into chilled 1.5 ml eppendorf tubes and centrifuged at 16,000 g for 10 min at 4°C until purification.

To generate fermentation broth for purification larger volumes were used as following. Single colonies of Mut+ strains for 24 hours. The yeast strains were cultivated as described above. 24 hours after the start of induction the OD600 of the cultures was measured and the samples corresponding to 5×10^7 cells (assuming OD600 of 1 correspond to 10^7 cells per ml) were quickly withdrawn into chilled 1.5 ml eppendorf tubes and briefly centrifuged at 16,000×g for 20 s. The supernatant was removed and the cell pellet resuspended in 200 μl RNALater solution (Ambion). The cells were incubated on ice for 30 min, then briefly centrifuged, the RNALater solution removed and the cells snap-frozen in liquid nitrogen and stored at −80°C until RNA isolation. The total RNA was isolated using RNAeasy Mini kit from Qiagen, the residual DNA was removed using TURBO DNA-free™ DNase from Ambion. The RT-PCR was carried out using Titan One Tube RT-PCR kit from Roche with AOX5 and AOX3 primers (Table 1). To ensure that the product results from RNA and not DNA, reactions with addition of only Taq polymerase instead of reverse transcriptase and DNA polymerase mix were carried out in parallel for all the reactions. The products of the reactions were analyzed on 1% agarose gel stained with SYBR-SAFE (Invitrogen).

### Table 1. List of primers.

<table>
<thead>
<tr>
<th>Primer Name</th>
<th>Sequence</th>
<th>Application</th>
</tr>
</thead>
<tbody>
<tr>
<td>vesv1_fw</td>
<td>Xhol 5'-CATCCTCGAGAAAAAGAAGCAGAAAAATCCGGCATTC</td>
<td>Amplification of vesv1 gene for cloning into expression vector pPICZαA</td>
</tr>
<tr>
<td>vesv1_rv</td>
<td>Khol 5'-GACGTCCTGAGGAGATCTTGGTGCTACG</td>
<td>Amplification of vesv5 gene for cloning into expression vector pPICZαA</td>
</tr>
<tr>
<td>vesv5_fw</td>
<td>Xhol 5'-CATCCTCGAGAAAAAGAAGCAGAAAAATCCGGCATTC</td>
<td>Amplification of vesv5 gene for cloning into expression vector pPICZαA</td>
</tr>
<tr>
<td>vesv5_rv</td>
<td>Khol 5'-TACTCTAGAGCTTTTTGATTAAAGTTC</td>
<td>Amplification of vesv5 gene for cloning into expression vector pPICZαA</td>
</tr>
<tr>
<td>Vesv1_S137A_fw</td>
<td>5'-CAGATTTCTGAGACCTTGGTGCTACG</td>
<td>Change of serine137 to alanine</td>
</tr>
<tr>
<td>Vesv1_S137A_rv</td>
<td>5'-GCGTGGAGACCTTGGTGCTACG</td>
<td>Change of aspartate165 to alanine</td>
</tr>
<tr>
<td>Vesv1_D165A_fw</td>
<td>5'-GAGATCTAGAGCTTTTTGATTAAAGTTC</td>
<td>Change of histidine229 to alanine</td>
</tr>
<tr>
<td>Vesv1_D165A_rv</td>
<td>5'-AGAAGGTAGCTTTTTGATTAAAGTTC</td>
<td>Change of histidine229 to alanine</td>
</tr>
<tr>
<td>Vesv1_H229A_fw</td>
<td>5'-CTTCTCGAGATTTCTGAGACCTTGGTGCTACG</td>
<td>Colony PCR to test the integration of inserts into the pPICZαA vector and RT-PCR</td>
</tr>
<tr>
<td>Vesv1_H229A_rv</td>
<td>5'-TTGGGTGCTCACGC</td>
<td>Colony PCR to test the integration of inserts into the pPICZαA vector and RT-PCR</td>
</tr>
<tr>
<td>AOX3</td>
<td>GCAATGGCATTCTGACATC</td>
<td>Colony PCR to test the integration of inserts into the pPICZαA vector and RT-PCR</td>
</tr>
<tr>
<td>AOX5</td>
<td>GCTGAGCACCCAA</td>
<td>Colony PCR to test the integration of inserts into the pPICZαA vector and RT-PCR</td>
</tr>
</tbody>
</table>

The altered triplets are emphasized in the primers used for directed point mutagenesis of vesv1 gene. Recognition sites for restriction endonucleases XbaI (TCTAGA) and XhoI (CTCGAG) are underlined.

doI:10.1371/journal.pone.0021267.t001
Western blot

For western blot the proteins were electrophoretically transferred onto 0.2 μm PVDF membrane Amersham Hybond™-P (GE Healthcare) using Mini Trans-Blot® electrophoretic transfer cell (Bio-Rad Laboratories) at 100 V for 1 hour. The transfer was done in 25 mM Tris, 192 mM glycine, and 20% v/v ethanol buffer. The membrane was blocked with the blocking reagent supplied together with Anti-His antibody (Qiagen) overnight, incubated with Anti-His antibody in blocking buffer (1:1,000) for 1.5 hour, washed with TBST buffer for 10 min three times and with TBS buffer for 5 min once. The bound antibody was detected by chemiluminescence with Amersham ECL™ Advance Western Blotting Detection Kit (GE Healthcare) and the signal was recorded with camera [Hamamatsu Photonics, Japan].

Enzymatic assays

Phospholipase A1 enzymatic assay was performed using EnzChek® phospholipase A1 assay kit from Invitrogen according to the manufacturer’s protocol with Lecitase® Ultra as a standard. The fermentation broth from the cells transformed with empty plasmids was used as background control. For the purified proteins the storage buffer (PBS with 30% glycerol) was used as background control. All measurements were performed at least in duplicates.

Purification with Ni-affinity chromatography

The proteins were recovered from the fermentation broth as following. Glycerol was added to the broth to the final concentration of 10% and 3 M NaCl to the final concentration of 300 mM. Detergent Tween 20 was added to the final concentration of 0.03%. The pH of the broth was adjusted to 7.5, the broth was centrifuged at 8,000×g for 15 min at 4°C and filtered through 0.45 μm filter. A 1-ml column was packed with Ni-NTA Superflow resin from Qiagen, washed with MilliQ water for 3 column volumes (CV) and equilibrated with 20 CV of buffer A (50 mM sodium phosphate, 300 mM NaCl, 10 mM imidazole, 10% glycerol, 0.03% Tween 20, pH 7.5) at 1 ml/min flow rate. The broth was loaded on the column at 1 ml/min, the column was...
Figure 2. Analysis of fermentation samples on Western blot. 10 µl of fermentation broth after 3-day induction on methanol at 20 and 30°C were analyzed by Western blot with anti-penta-His antibody. For several strains up to 4 transformants were tested and no significant difference between clones was observed. The marker is a pre-stained PageRuler (Fermentas, Germany). Lot-to-lot variation of the apparent molecular weight of pre-stained proteins in the ladder is ~5%.

doi:10.1371/journal.pone.0021267.g002

Figure 3. Recombinant proteins concentration and enzymatic activity. Concentration of recombinant protein in fermentation broth (same samples as on Figure 2) were measured by ELISA with anti-penta-His antibody (A). Phospholipase A1 enzymatic activity was measured in a fluorometric commercial assay (Invitrogen) (B).

doi:10.1371/journal.pone.0021267.g003
washed with at least 20 CV of buffer A and the protein was eluted with buffer B, which differed from buffer A by a higher imidazole concentration of 250 mM. The fractions containing the protein were pooled and desalted on Zeba™ Desalt Spin Columns (Thermo Scientific). Protein concentration was measured by amino acids analysis [24,25]. The proteins were resuspended in PBS buffer with 30% glycerol and stored at −20°C.

Quantification of 6-HIS-tagged proteins by ELISA

Maxisorb microtiter plates (Nunc, Denmark) were coated with 100 µl samples diluted 1:10 or 1:100 in PBS buffer. The standard curve was made with serial double-fold dilutions of purified rVes v 1 H229A, which concentration was determined by amino acids analysis. The coating was performed at 4°C overnight. The plates were washed with phosphate-buffered saline with 0.1% Tween20 (PBST) and blocked with 200 µl PBSTM (5% skim milk in PBST) for 1 hour at room temperature. The plates were washed with PBST and incubated for 2 hours at room temperature with anti-penta-his HRP-conjugated antibody (Qiagen) diluted 1:500 in PBSTM. The plates were washed with PBST after which 100 µl of TMB ONE liquid substrate (Kem-En-Tek Diagnostics A/S, Denmark) reagent was added to each well and the reaction was allowed to proceed for 10 min at room temperature in the dark. The reaction was terminated by addition of equal volume of 0.9 M H2SO4. And the absorbance was measured at 450 nm using Synergy reader (BioTek).

Quantification of IgE binding and inhibition by Enzyme Allergo-Sorbent Test (EAST)

Maxisorb microtiter plates were coated with purified recombinant allergens at the concentration 3 µg/ml in DPBS buffer (Gibco) or with venom extract diluted with DPBS to the final concentration of 10,000 SQ/ml. The coating was performed at room temperature overnight. The plates were washed with ELISA buffer (Pharmacy of the Danish Capital Region), blocked with blocking/sample buffer (1% BSA, 0.1% Tween 20 in DPBS) for 2 hours at 37°C, washed again with ELISA buffer and incubated with shaking at room temperature overnight with patients serum diluted 1:10 in sample buffer. The plates were washed, incubated with 1:250 Biotin Mouse a-Human IgE (BD) in sample buffer for 2 hours at 37°C, washed, incubated with 1:2000 ExtrAvidin-Peroxidase (Sigma) in sample buffer for 30 min at room temperature, washed again and developed with OPD reagent (Dako) as recommended by manufacturer.

For inhibition assays the serum was pre-incubated with recombinant allergen or wasp venom in sample buffer (1:20) at 4°C overnight before loading on the coated plates.

Histamine release assay

Peripheral blood mononuclear cells (PBMCs) from buffy coat blood (non-allergic donor, anti-IgE responsive cells) were isolated by Lymphoprep gradient centrifugation. IgE was stripped off the basophils by a rebound in pH from 7.4 to 3.55 and back to 7.4. The PBMCs were then incubated 1 hour with wasp patient or control pool (non-allergic) serum to re-sensitize the basophils, which subsequently were mixed with erythrocytes and challenged in glass coated microtiter plates (RefLab, Copenhagen, Denmark) with wasp venom extract or with purified recombinant allergens. Released histamine bound to the glass fibers was coupled to o-phtaldialdehyde, stabilized by HClO4, and measured fluorometrically as described previously [26]. Results were expressed as percentage of total cellular histamine content and were considered positive when >10%.

Protein analysis by MALDI-TOF

Protein spots were picked from Coomassie-stained gels. Tryptic digestion was carried out as previously described [27]. The peptide solution was applied on Anchorchip targetTM (Bruker Daltonics) using CHCA as matrix. MS analysis was performed on a MALDI-TOF-TOF Ultraflex II in positive ion reflector mode and spectra were processed and analyzed using the software FlexAnalysis and BioTools (Bruker Daltonics). Database searching was carried out for each individual sample using an in-house MASCOT server (Matrix Science, London, UK) to search NCBI nr [ftp://ftp.ncbi.nlm.nih.gov/blast/db/]. The search criteria were selected as following: peptide tolerance ±50 ppm, fixed modifications – carbamidomethyl (C), variable modifications – oxidation (M), allow up to 1 missed tryptin cleavages.

Results

Cloning and mutation of phospholipase A1

We previously isolated a Vesv1 gene encoding wasp venom phospholipase A1 from a local Danish species of V. vulgans. On the inspection of the sequence we found that it contained some longer AT-rich stretches, which could serve as premature termination signals to yeast (Figure 1). To avoid incomplete transcription of the gene in the recombinant host we optimized the gene sequence using online tool provided by Mr.Gene GmbH (Germany). During the optimisation the most common P. pastoris codons were preferred, though synonymous codons were used as well to avoid excessive repetitions and restriction sites. We avoided restriction sites necessary for cloning and plasmid linearization as well as yeast splice donor sites, poly(A)-sites, TATA-boxes, RBS, and −35 prokaria boxes.
The synthetic gene was cloned in expression plasmid pPICZαA after the strong methanol-inducible alcohol oxidase 1 (AOX1) promoter and in-frame with the α-mating factor pre-propeptide for secretion from the cells. The genes were fused with c-myc and 6×HIS tags at the C-terminus for easy detection and purification. The resulting plasmid was mutated to substitute three different amino acids from the predicted active site, serine137, aspartate165 and histidine229 to alanine (Figure 1). The 3D modelling of the mutated Ves v 1 variants was performed as well and the mutated versions aligned well with the wild-type model, indicating that the introduced mutations should not cause significant changes in the 3D structure of the molecule. The resulting plasmids with wild-type and mutated variants of the Ves v 1 gene were introduced into two P. pastoris strains: wild type X33 strain with an active AOX1 gene giving fast growth on methanol (Mut+ phenotype) and strain KM71H with a deletion in AOX1 gene resulting in slow growth on methanol (MutS phenotype). Induction was performed in complex medium in shake flasks at 20°C or 30°C. The induction of KM71H strain was performed with a 1:1 mixture of glycerol and methanol because we found in preliminary experiments that it gave better final product titer than induction with pure methanol (data not shown).

Expression of active phospholipase A1 and its mutated variants

Fermentation broth was analyzed for the presence and size of recombinant proteins using Western blot (Figure 2). The concentrations of recombinant proteins in the broth were measured by ELISA and phospholipase A1 activity was analyzed in enzymatic assay (Figure 3). While phospholipase A1 enzymatic activity was detected in the broth of cultures expressing a wild-type version of Ves v 1 gene, the protein could not be detected on Western blot under any expression conditions. The reason could be too low expression levels of the protein or partial degradation of the protein with a loss of the C-terminal tag.

To ensure that Ves v 1 gene was transcribed, we performed RT-PCR (Figure 4) and could show that the gene was expressed, though at a lower level than the mutated forms of Ves v 1 if AOX1 expression is taken as a reference for comparison. The strains expressing the active form of phospholipase A1 grew poorly on methanol-containing plates in spite of the presence of the active AOX1 gene as confirmed by colony PCR. We attempted high-cell density cultivation of a P. pastoris strain expressing active Ves v 1 gene to see if higher yields could be obtained, however the culture went into growth arrest at the switch to the inducing substrate methanol even though the substrate was introduced at very low feed rate (data not shown).

The mutated versions of rVes v 1 of the expected size of 36 kDa could be detected in fermentation broth by Western blot. The expression was slightly better at 20°C than at 30°C both in Mut+ and MutS strains as measured by ELISA. The comparison between the Mut+ or MutS strains is not very relevant in this

![Figure 5. Purification of rVes v 1 H229A.](image_url) The enzymatically inactive protein was purified from P. pastoris fermentation broth using Ni-affinity chromatography. 10 µl samples of the fermentation broth, flow-through, wash and elution fractions were separated on SDS-PAGE and silver-stained. The size marker is 5 µl of 10-fold diluted unstained PageRuler (Fermentas). doi:10.1371/journal.pone.0021267.g005
contest as the optimal induction times for these two strains can differ.

It can also be concluded that the proteins with modifications S137A and D165A were in general expressed poorer than the protein with modification H229A and this also correlates with the presence of some residual phospholipase 1 activity in the fermentation broth of those two variants, while H229A protein does not have a detectable PLA1-activity. Silver-stained SDS-PAGE of the fermentation broth of KM71H strains expressing active rVes v 1 or partially active rVes v 1 D165A shows abundant protein bands, while much fewer proteins and at lower concentrations are seen for the strain expressing empty plasmid or enzymatically inactive form of Ves v 1 (data not shown). This could be a sign of cell lysis due to destruction of cell membrane by the secreted phospholipase A1.

Purification and characterisation of enzymatically inactive rVes v 1 H229A

We purified the rVes v 1 protein with mutation H229A from fermentation broth of 120-hour shake flask culture of KM71H strain. 1.7 mg/L was purified using Ni-affinity chromatography (Figure 5). The purification conditions were quite stringent as we wanted to obtain as pure protein as possible, otherwise higher yield could be obtained. Besides the 36 kDa protein band corresponding to rVes v 1 H229A monomer, a weak 72 kDa band was observed in a few elution fractions with the highest protein concentration. This is most likely a protein dimer appearing due to inter-disulphide bridge formation. The 72-kDa artefact disappeared after protein desalting and dilution in storage buffer (Figure 6). The 36 kDa protein was analyzed by MALDI-TOF MS (Figure 6) and was identified as *V. vulgaris* phospholipase A1.

![Figure 6. SDS-PAGE gel of venom and purified rVes v 1 H229A and rVes v 5.](image)

1,000 SQ units of venom extract and 300 ng of purified rVes v 1 H229A and rVes v 5 were separated on SDS-PAGE and stained with coomassie. The identity of recombinant allergens and of the native nVes v 1 and nVes v 5 proteins in the venom was confirmed by MALDI-TOF MS.

doi:10.1371/journal.pone.0021267.g006

![Figure 7. Binding of IgE antibodies from allergic patients sera to rVes v 1 H229A and rVes v 5 as measured by EAST.](image)

EAST results are shown for twenty two sera. 5 sera (A, B, C, D and control serum) were chosen for further studies. Two sera (A and B) showed a positive response to rVes v 1 H229A and negative to rVes v 5, one serum (C) showed the contrary, serum D was positive for both allergens, while control serum did not react with either of the allergens.

doi:10.1371/journal.pone.0021267.g007
with 10 independent peptides matching with a mass tolerance of 50 ppm and with protein sequence coverage of 39% (p<0.05). Several bands in the wasp venom extract were analyzed by MALDI-TOF MS as well and the bands corresponding to the native phospholipase A1 and antigen 5 were found with significance p<0.05 (Figure 6). The recombinant proteins have a size 2.7 kDa larger than the native allergens due to the presence of the C-terminal tag.

IgE binding of rVes v 1 H229A

The ability of rVes v 1 H229A to bind specific IgE antibodies was investigated in EAST assays with sera from the wasp-allergic patients. The presence of antigen 5-specific IgEs was tested as well. Twenty-two sera were selected that had a high reactivity to wasp venom and no reactivity to honey-bee venom in ImmunoCAP tests. By choosing the sera that did not cross-react with honey-bee venom we avoided the interference of specific IgE antibodies directed towards carbohydrate determinants. Out of 22 sera 14 (64%) reacted with both rVes v 1 H229A and antigen 5, 4 (18%) reacted with only Ves v 1 H229A, 2 (9%) with only antigen 5 and 2 (9%) did not react with either of the allergens (Figure 7). The latter group of patients could be sensitized to other components of the wasp venom as the peptide bone of hyaluronidase or dipeptidyl peptidase IV. The control non-allergic sera did not react with either of the recombinant allergens.

Two sera (A and B), which reacted with rVes v 1 H229A, but not with rVes v 5, were chosen for inhibition study, where the plates were coated with venom extract and the binding of sera to the venom was inhibited with different concentrations of recombinant rVes v 1 H229A (Figure 8). Binding of serum A to wasp venom was completely inhibited both by venom itself and by rVes v 1 H229A. For serum B the maximal inhibition by rVes v 1 H229A was 75%, whereas venom gave 96% inhibition.

Histamine release by rVes v 1 H229A

Histamine release (HR) from basophils sensitised with IgE antibodies from allergic or control sera was used to test the immunological activity of the recombinant allergens rVes v 1 H229A and rVes v 5, and wasp venom (Figure 9). The histamine release assay is more sensitive than EAST inhibition and positive response (above 10% histamine release) could be detected for recombinant allergens concentrations as low as 10 ng/ml. As illustrated in Figure 9, serum A showed histamine release with rVes v 1 H229A and venom, but not with rVes v 5. Serum B, however, showed release with both allergens, indicating that the lack of detection of rVes v 5 response in EAST attributes to the lower sensitivity of the assay. Reactivity of serum B IgE antibodies towards rVes v 5 explains why the binding to venom could not be completely inhibited with rVes v 1 H229A in the EAST inhibition assay. Serum C, which was characterized as rVes v 1 H229A-negative, rVes v 5-
positive in the EAST assay, behaved in the same way in HR assay mediating HR with only Ves v5 and venom. HR results for the Ves v1 H229A and Ves v 5 double positive serum (D) and for the control serum were also consistent with EAST results, showing response for both recombinant allergens and venom with serum D, but no HR with control serum, respectively.

**Discussion**

Specific immunotherapy (SIT) is used for treatment of various allergies, where wasp and honey bee venom allergy, birch and grass pollen allergy, house dust mites allergy are but a few examples. Conventional allergy vaccines are partially purified allergenic extracts, which can differ in batch-to-batch composition and are difficult to standardize. The recent developments in cloning and characterization of recombinant allergens have paved the way for the new generation of recombinant allergy vaccines, which can be produced with a high-consistent quality under good manufacturing practice conditions. Moreover, they allow composing patient-tailored vaccines according to patients’ individual sensitization profiles. Recombinant birch pollen allergen Bet v 1 and a cocktail of recombinant grass pollen allergens have been
shown to be efficient and safe for allergy treatment in human trials [28,29]. To the best of our knowledge, there is no clinical data on recombinant venom immunotherapy, though some animal testing has been conducted showing efficacy of a honey bee fusion vaccine, combining T-cell epitopes of three allergens [30], and of wasp venom antigen 5 in murine model [31].

Availability of recombinant wasp venom allergens produced in a safe expression host is an obstacle in developing recombinant immunotherapy. While all of the allergens have been expressed in baculovirus system and are well-suited for diagnostic purposes, for therapeutic purposes it is desirable to produce the allergens in a host cell surface for industrial production. One of the major allergens from the wasp venom, antigen 5, was successfully expressed in a eukaryotic host yeast P. pastoris previously, and here we expressed another major allergen, phospholipase A1.

We previously found that expression of phospholipase A1 on the surface of another yeast S. cerevisiae causes 70–82% growth inhibition [12]. Indeed our attempts to express an enzymatically active phospholipase A1 in yeast P. pastoris resulted in defective cell growth on plates and lead to cell lysis upon induction of expression in fermentors. We therefore decided to express an enzymatically inactive version of the protein instead. Such a protein, presuming that its immunological and allergenic properties are preserved, might be better suited for immunotherapy as it would not cause side-effects due phospholipases degradation. We performed single point mutations replacing the amino acids in the predicted active site of the protein with alanine. The 3D modeling of the active and mutated molecules did not show any significant changes of the protein structure due to the mutations. Three mutated versions of the allergen were expressed in P. pastoris. One of the variants, with mutation H229A, had no detectable phospholipase A1 activity and was secreted by P. pastoris at higher yields than other two forms. Although enzymatically inactive, the protein preserved its IgE binding activity as shown in EAST and inhibition EAST using serum from wasp venom allergic patients, it was also immunological activity illustrated by its capability to mediated histamine release from basophils sensitized with wasp venom specific IgE.

The yield of pure recombinant protein was 1.7 mg/L fermentation broth. The yield can be further enhanced by strain improvement, where either a rational approach can be undertaken with optimization of promoter, signal sequence, copy number in the genome or a simple screening of a larger number of clones can be carried out. The fact that expression of Ves v 1 was higher at lower temperature (20°C instead of 30°C) indicates possible limited capacity of the cells to properly fold the given protein. If this is the case, usage of a weaker promoter could be an advantage as this would prevent the occurrence of the unfolded protein response. Furthermore fermentation can be optimized, where high cell-density cultivations can routinely give order of magnitude higher yields than shake flask cultures.

In conclusion, we established expression of an enzymatically inactive wasp venom allergen rVes v 1 in methyloptrophic yeast P. pastoris. The protein had histidine 229 in the enzyme active site replaced by alanine. The protein showed immunological activity in EAST and histamine release assay and could inhibit the binding of Ves v 1-reactive sera to wasp venom. It presents a candidate of recombinant immunotherapy, particularly in combination with another major wasp venom allergen rVes v 5, which has also been produced in P. pastoris.

Acknowledgments

We thank Anne Blicher from Enzyme and Protein Center (Technical University of Denmark, Denmark) for amino acids analysis and for assistance with MALDI-TOF MS analysis.

Author Contributions

Conceived and designed the experiments: IB BMJ MAH LKP. Performed the experiments: IB BMJ TW. Analyzed the data: IB BMJ LKP. Contributed reagents/materials/analysis tools: IB BMJ MAH KLP. Wrote the paper: IB BMJ MAH IS LKP.

References


